Overview

Oncolytic Virus H101 Combined With Lenvatinib Plus Toripalimab Compared With FOLFOX in Patients With Advanced Biliary Tract Cancer (OPTIONS-06)

Status:
NOT_YET_RECRUITING

Trial end date:
2027-05-01

Target enrollment:

Participant gender:

Summary

This study will evaluate the efficacy and safety of Oncolytic virus H101 combined with lenvatinib plus Toripalimab compared with FOLFOX in patients with advanced biliary tract cancer (BTC) who have progressed after first-line treatment.

Phase:

PHASE2

Details

Lead Sponsor:

Fudan University

Treatments:

Folfox protocol
lenvatinib